Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The purpose of this article is to describe dependence and withdrawal phenomena related to CNS drugs discontinuation and to clarify issues related to the evaluation of clinical drug withdrawal and rebound as they relate to safety in new drug development. The article presents current understanding and definitions of drug dependence and withdrawal which are also relevant and important features of addiction, though not the same. Addiction, called substance use disorder in DSM-5, affects an individual’s brain and behaviour, represents uncontrollable drug abuse and inability to stop taking a drug regardless of the harm it causes. Characteristic withdrawal syndromes following abrupt discontinuation of CNS-active drugs from numerous drug classes are described. These include drugs both scheduled and non-scheduled in the Controlled Substances Act, which categorizes drugs in five schedules based on their relative abuse potentials and dependence liabilities and for regulatory purposes. Schedules 1 and 2 contain drugs identified as those with the highest abuse potential and strictest regulations. Less recognized aspects of drug withdrawal, such as rebound and protracted withdrawal syndromes for several drug classes are also addressed. Part I presents relevant definitions and describes clinical withdrawal and dependence phenomena. Part II reviews known withdrawal syndromes for the different drug classes, Part III describes rebound and Part IV describes protracted withdrawal syndromes. To our knowledge, this is the first compilation of withdrawal syndromes for CNS drugs. Part V provides details of evaluation of dependence and withdrawal in the clinical trials for CNS drugs, which includes general design recommendations, and several tools, such as withdrawal questionnaires and multiple scales that are helpful in the systematic evaluation of withdrawal. The limitations of different aspects of this method of dependence and withdrawal evaluation are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About half of the patients on antidepressants who try to discontinue or reduce the dose experience withdrawal symptoms”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In basic pharmacology and addiction medicine, these neurophysiological adaptations are typically defined as physical dependence (no to be confused with addiction) and a withdrawal syndrome upon dose reduction or treatment discontinuation is its sole clinical manifestation (Horowitz et al., 2023; Horowitz and Taylor, 2023; Lerner and Klein, 2019).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lerner and Klein, 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This process of re-setting of neurons and networks has been estimated to take between hours and years (although research is lacking in this area).20,21”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence suggests that physiological adaptations to opioid dependence might take months or years to resolve.”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [21]
Experimental — accuracy not yet measured
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment
Barkley, R. A., & Poillion, M. J. (1994) · Behavioral Disorders · doi:10.1177/019874299401900205 · Cited by 4,639
Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment
SPRAFKIN, J., & CARLSON, G. A. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1266 · Cited by 1,900
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,731
Addiction and the brain antireward system
Koob, G. F., & Le Moal, M. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.103006.093548 · Cited by 1,457
Rosen's emergency medicine : concepts and clinical practice.
Marx, J. A. (2017) · Cited by 1,258
Rosenʼs emergency medicine: concepts and clinical practice
Rotheray, K. R., & Cattermole, G. N. (2010) · European Journal of Emergency Medicine · doi:10.1097/mej.0b013e32833728f4 · Cited by 1,120
Hudak, M. L., Tan, R. C., THE COMMITTEE ON DRUGS, THE COMMITTEE ON FETUS AND NEWBORN, Frattarelli, D. A. C., Galinkin, J. L., Green, T. P., Neville, K. A., Paul, I. M., Van Den Anker, J. N., et al. (2012) · Pediatrics · doi:10.1542/peds.2011-3212 · Cited by 877
Effects of abstinence from tobacco: Valid symptoms and time course
Hughes, J. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701188919 · Cited by 801 · cited 1×
“Tobacco/nicotine withdrawal usually begins within 24– 72 h of stopping or decreasing tobacco use, peaks at 2– 3 days after abstinence, and lasts 2–4 weeks (Hughes, 2007; New South Wales Government, 2008; APA, 2013; Jackson et al., 2015) and label Nicotrol 2010, Table 1.”
BackgroundSubstance Abuse and Mental Health Services Administration
(2009) · Encyclopedia of Substance Abuse Prevention, Treatment, & Recovery · doi:10.4135/9781412964500.n301 · Cited by 720
Research works printed but not linked: 3
- 2013, Diagnostic and statistical manual of mental disorders, 5th Edition: DSM-5
- Himmelsbach, 1939, Studies of certain addiction characteristics of (a) dihydromorphine (“Paramorphan”); (b) dihydrodesoxymorphineD (“Desomorphine”); (c) dihydrodesoxycodeine (“Desocodeine”) and (d) methyldihydromorphinone (“Metopon”), Pharmacol Exp Ther, 67, 239
- 2008, Ministry of Health NG, AU
Cited by
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Clinical management of cannabis withdrawal
Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021) · Addiction · doi:10.1111/add.15743 · Cited by 135
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76
“Therefore, “For drugs not associated with abuse potential, an individual may still develop dependence; but again, this would not be classified as an addiction” [21].”
BackgroundHengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Metadata
- Authors
- Lerner, A., & Klein, M.
- Affiliations
- United States Food and Drug Administration (US)
- Controlled Substance Scientific Solutions LLC, 4601 North Park Avenue #506, Chevy Chase, MD 20815-4572, USA
- Corresponding author
- Lerner, Alicja
- Klein, Michael
- Venue
- Brain Communications
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-01
- Volume
- 1
- Issue
- 1
- Pages
- fcz025-fcz025
- ISSN
- 2632-1297 (ISSN-L)
- PMC
- PMC7425303
- OpenAlex
- W2980350741
- Semantic Scholar
- 89034519e35d0ae0d84d1831e16309eaa7352028
- Cited by
- 89
- References
- 200
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 16 · 2023: 17 · 2022: 11 · 2021: 12 · 2020: 6
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Brain Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Oak Ridge Institute for Science and Education
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- drug addiction, drug withdrawal, rebound, central nervous system drugs, withdrawal syndrome, addiction, substance use disorders, Controlled Substances Act, drug scheduling, new drug development, clinical trial design, drug safety assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.